Wide Ranks

ANVS

Annovis Bio, Inc.

6.54

Top Statistics
Market Cap 90 M Forward PE -7.52 Revenue Growth 0.00 %
Current Ratio 2.66 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 12 M Total Cash Per Share 0.9160 Total Debt
Total Debt To Equity Current Ratio 2.66 Book Value Per Share 0.5320
All Measures
Short Ratio 402.00 % Message Board Id finmb_622711087 Shares Short Prior Month 1 M
Return On Equity -5.97 City Malvern Uuid e153bc75-9830-375d-bf5e-330db4df878a
Previous Close 6.56 First Trade Date Epoch Utc 1 B Book Value 0.5320
Volume 177687 Price To Book 12.29 Fifty Two Week Low 4.53
Total Cash Per Share 0.9160 Shares Short Previous Month Date 1 B Target Median Price 26.00
Max Age 86400 Recommendation Mean 1.67 Sand P52 Week Change 0.3133
Target Mean Price 34.80 Net Income To Common -40939112 Ask 6.51
Short Percent Of Float 0.1269 Implied Shares Outstanding 13 M Last Fiscal Year End 1 B
Trailing Peg Ratio None Average Daily Volume10 Day 216240 Average Volume10days 216240
Total Cash 12 M Next Fiscal Year End 1 B Held Percent Insiders 0.2040
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 6.56 Target Low Price 21.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 8.17 Open 6.71 Free Cashflow -11572214
State PA Dividend Yield 0.00 % Return On Assets -1.55
Time Zone Short Name EST Trailing Eps -4.22 Day Low 6.36
Address1 101 Lindenwood Drive Shares Outstanding 13 M Price Hint 2
Target High Price 72.00 Website https://www.annovisbio.com 52 Week Change -0.2297
Average Volume 234571 Forward Eps -1.81 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 234.40 % Is_sp_500 False
Regular Market Day High 6.75 Profit Margins 0.00 % Fifty Two Week High 22.49
Day High 6.75 Shares Short 1 M Regular Market Open 6.71
Industry Key biotechnology Bid 6.34 Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.1010 Operating Cashflow -22974234
Currency USD Time Zone Full Name America/New_York Market Cap 90 M
Is_nasdaq_100 False Zip 19355 Quote Type EQUITY
Industry Biotechnology Long Name Annovis Bio, Inc. Regular Market Day Low 6.36
Held Percent Institutions 0.0883 Current Price 6.54 Address2 Suite 225
Financial Currency USD Current Ratio 2.66 Industry Disp Biotechnology
Number Of Analyst Opinions 5 Country United States Float Shares 10 M
Two Hundred Day Average 8.81 Enterprise Value 77 M Forward PE -7.52
Regular Market Volume 177687 Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.

The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.

The company was incorporated in 2008 and is based in Malvern, Pennsylvania.